MediWound (MDWD) EVP Meyer Yaron files Form 3 on equity holdings

Rhea-AI Filing Summary

MediWound Ltd. executive Meyer Yaron, EVP, General Counsel and Corporate Secretary, filed an initial Form 3 reporting his beneficial ownership in ordinary shares and stock options of MDWD.

The filing lists several stock option grants to buy ordinary shares, including options over 2,857 underlying shares at an exercise price of 36.0500 expiring on December 31, 2028, and 4,919 underlying shares at 12.2500 expiring on April 23, 2030. Additional grants cover 2,769 underlying shares at 37.5200 expiring on March 4, 2031, 9,230 underlying shares at 14.4200 expiring on May 16, 2032, and further awards expiring through 2036.

Yaron also reports direct holdings of ordinary shares tied to restricted stock units (RSUs). Footnotes explain RSU and option grants made on February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026, each vesting 25% on the one-year anniversary of grant and 6.25% quarterly thereafter until fully vested after four years.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Meyer Yaron

(Last) (First) (Middle)

C/O MEDIWOUND LTD.

42 HAYARKON STREET

(Street)

YAVNE 8122745

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
MediWound Ltd. [ MDWD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GC & Corp. Secretary

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares	1,413	D
Ordinary shares(1)	1,200	D
Ordinary shares(2)	2,357	D
Ordinary shares(3)	1,750	D
Ordinary shares(4)	1,850	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy ordinary shares)	12/31/2022	12/31/2028	Ordinary shares	2,857	$36.05	D
Stock Option (right to buy ordinary shares)	04/23/2024	04/23/2030	Ordinary shares	4,919	$12.25	D
Stock Option (right to buy ordinary shares)	03/04/2025	03/04/2031	Ordinary shares	2,769	$37.52	D
Stock Option (right to buy ordinary shares)	(5)	05/16/2032	Ordinary shares	9,230	$14.42	D
Stock Option (right to buy ordinary shares)	(6)	02/15/2033	Ordinary shares	7,200	$13.32	D
Stock Option (right to buy ordinary shares)	(7)	02/26/2034	Ordinary shares	18,855	$12.729	D
Stock Option (right to buy ordinary shares)	(8)	02/11/2035	Ordinary shares	14,000	$18.54	D
Stock Option (right to buy ordinary shares)	(9)	03/04/2036	Ordinary shares	15,000	$17.6	D

Explanation of Responses:

1. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

3. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

4. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the RSUs vested upon the one-year anniversary of the grant date, and an additional 6.25% of the RSUs vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

5. The options reported in this row were granted to the Reporting Person on May 16, 2022 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

6. The options reported in this row were granted to the Reporting Person on February 15, 2023 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

7. The options reported in this row were granted to the Reporting Person on February 26, 2024 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

8. The options reported in this row were granted to the Reporting Person on February 11, 2025 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

9. The options reported in this row were granted to the Reporting Person on March 4, 2026 and vest in accordance with the following schedule: 25% of the options vested upon the one-year anniversary of the grant date, and an additional 6.25% of the options vest equally on a quarterly basis over the following three years such that they will be fully vested on the four-year anniversary of the grant date.

	/s/ Yaron Meyer	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Meyer Yaron’s Form 3 report for MediWound (MDWD)?

The Form 3 reports initial beneficial ownership for executive Meyer Yaron at MediWound. It lists his direct holdings of ordinary shares plus multiple stock option and RSU grants, detailing exercise prices, expiration dates, and four-year vesting schedules for each award.

Which stock options are disclosed for Meyer Yaron in MDWD?

The filing discloses several stock option grants to buy MediWound ordinary shares, including 2,857 underlying shares at 36.0500 expiring December 31, 2028 and 4,919 underlying shares at 12.2500 expiring April 23, 2030, plus additional grants expiring through 2036.

How do Meyer Yaron’s MediWound RSUs vest over time?

The RSUs for Meyer Yaron vest over four years. For each grant, 25% of RSUs vest on the one-year anniversary of the grant date, then 6.25% of the RSUs vest quarterly over the next three years until fully vested at the four-year mark.

Which grant dates are referenced in MDWD’s Form 3 footnotes?

Footnotes reference equity grants on February 15, 2023, February 26, 2024, February 11, 2025, and March 4, 2026. They describe RSU and option awards to Meyer Yaron, including identical 25% first-year and 6.25% quarterly vesting schedules over four years.

Does the MediWound Form 3 show any stock purchases or sales by Meyer Yaron?

The Form 3 presents holding entries only, not open-market purchases or sales. It describes existing ordinary share, option, and RSU positions for Meyer Yaron, with 13 holding entries categorized and no transactions marked as buys, sells, exercises, gifts, or tax-withholding.